Recent advances in understanding and treating Alzheimer's disease

Abstract

Background: Alzheimer’s disease (AD) still counts as a huge global health issue, with a steady slide in thinking ability and neurodegeneration. Over time, progress tied to the amyloid and tau ideas, plus work on neuroinflammation, and genetic risk signals like APOE ε4, has really broadened the way people understand AD as a kind of many-cause condition, even if the details stay complicated. Objective: The aim here is sort of to look over what’s new in the diagnosis, treatment, and day to day management of AD, and to point out what problems still don’t fully get solved in the field. Methods: This narrative review gathers together and connects recent updates across diagnostic biomarkers, imaging approaches, pharmacological and non-pharmacological interventions, and newer experimental directions that might shape future therapy for AD. Results: Diagnostic accuracy has gotten better, in part because cerebrospinal fluid and blood-based biomarkers now offer more dependable signals. Also, advanced neuroimaging such as PET and MRI, along with improved neuropsychological assessment tools, helps clinicians catch AD earlier than before. On the treatment side, disease modifying agents aimed at amyloid and tau pathology have moved forward, including the approval of aducanumab, though the overall picture is still being refined. Meanwhile, symptom-focused therapies keep helping people manage cognitive and behavioral issues, day by day. Lifestyle approaches diet, physical activity, and cognitive training look promising as add-on strategies, potentially slowing down progression rather than reversing anything. New and still investigational ideas, like gene therapy and stem cell-based interventions, could become future routes for disease modification. Even so, the gap remains: AD shows clinical and biological heterogeneity, clinical trials can be hard to set up and run, and patient recruitment is often a bottleneck. On top of that, ethical concerns keep coming up around very early diagnosis, and whether treatment access stays fair for everyone. Conclusion: there has been solid progress in figuring out AD pathophysiology and enhancing both diagnostic and therapeutic approaches, but a definitive cure still seems to stay out of reach. It’s still important to keep up interdisciplinary research and collaboration, so we can tackle the open issues, sharpen early detection and tailor individualized treatment strategies, and in the end, improve results for patients and families that are affected by AD.